Don’t miss my discussion with Roger Longman, CEO of Real Endpoints, as we dive into the hotly contested issue of drug pricing in America. You’ll understand why Fortune Magazine named Roger to the drug pricing “Dream Team” (March, 2016 issue) as someone who could help fix the problem.
You’ll hear Roger’s insights on the following:
Is it fair to point the finger at the drug makers for the unsustainable pricing of prescription drugs today?
What should pharma and biotech companies being doing differently given the current climate?
What can payers and PBMs be doing differently?
What kind of talent is needed in the pharma and payer sectors?
Why the big focus on orphan and specialty drugs. Don’t we need more focus on common chronic illnesses, such as diabetes?
What is the future of outcomes-based reimbursement?
Learn how Real Endpoints helps payers and pharma companies to be more savvy in dealing with today’s unpredictable environment.